MUSK and myasthenia gravis: Rituximab, a chimeric anti-CD20 monoclonal antibody known for B-cell depletion, has shown encouraging results in treating MuSK-Ab-positive MG patients according to various clinical observations, and is even reported to help reduce the use of steroids (12, 18–27).